Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1Phase 4 1Phase 3 1

Status

Completed 28Unknown 3Withdrawn 1Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 1

Interventions

Metformin 3Letrozole 3Sperm Injections, Intracytoplasmic 2Progesterone 2Lidocaine 2Indocyanine Green 2Gentamicins 2Estradiol 2Clomiphene 2Bevacizumab 2Acitretin 2tirbanibulin 1technetium Tc 99m nanocolloid 1suvorexant 1pomalidomide 1pembrolizumab 1pasireotide 1nilotinib 1methylnaltrexone 1ledipasvir 1ixazomib 1gadolinium ethoxybenzyl DTPA 1gadofosveset trisodium 1exemestane 1encorafenib 1dolutegravir 1ceftolozane, tazobactam drug combination 1binimetinib 1bicalutamide 1apatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Withdrawn × Zoledronic Acid × Clear all
NCT00242528 2015-04-14

Open-label Study, to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Bone Lesions Secondary to Multiple Myeloma.

Novartis

Phase 4 Withdrawn
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡